Compare Otis Worldwide Corp (OTIS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs Sanofi SA — how do they compare? Otis Worldwide Corp trades at $65.98 (market cap $25.17B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3.8× Otis Worldwide Corp's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Otis Worldwide Corp for 66 Days and Sanofi SA for 94 Days on average.
| OTIS | SNY | |
|---|---|---|
Market Cap | $25.17B | $95.18B |
Volume | 4,542,442 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $93.62 | $52.34 |
52-Week Low | $64.05 | $39.51 |
Typical Hold Time | 66 Days | 94 Days |
Enterprise Value | $33.20B | $114.48B |
Dividend Yield | 2.66% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide trades at $65.95, showing modest daily gains of 0.32% but remains near its 52-week low. The stock faces technical bearish signals with mixed fundamental performance - revenue growth remains stable at $14.43B (2025) but recent quarters show earnings misses. Analyst consensus is divided with 7 buy, 7 hold, and 1 sell ratings, while the company navigates margin pressures and China market challenges.
The outlook balances Otis's dominant market position and service-driven cash flows against margin pressures and weak equipment demand. With a $87 consensus price target suggesting 32% upside, the stock offers value but requires monitoring of service margin recovery and China exposure. Key risks include persistent cost inflation and execution challenges in key markets.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
